The Parsortix cell separation system successfully developed by ANGLE plc has moved into the regulatory authorisation and market launch phase. The system captures intact circulating tumor cells from cancer patient blood and has been positively evaluated by research partners. ANGLE is now focused on securing the necessary regulatory approvals to commercialize the Parsortix system and address the multi-billion dollar clinical cancer treatment market.

1. Parsortix PR1 System successfully developed
Moving into regulatory authorisation and
market launch phase
Andrew Newland and Ian Griffiths
31 July 2013

2. © ANGLE plc 2013 Page 2
Legal disclaimer
The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment
(without notice), verification and completeness.
This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly
or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to recipients on
the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in
connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into
the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be
distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States
Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe
for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or
used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal
requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular,
should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America
(or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any
citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof
or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory
requirement. Any such distribution could result in violation of the laws of such countries.
This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase
any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose
whatsoever on the information, representation or opinions.
This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors,
officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent
assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular,
any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis
and assumptions and each recipient should satisfy itself in relation to such matters.
Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the
accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any
responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising
in connection therewith.
Forward-Looking Statements
This presentation and the associated commentary contains certain forward-looking statements based on current expectations,
forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently
available to the Company; and actual results could differ materially from those stated or implied, due to risks and uncertainties
associated with its business. Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies
regarding the future and can be identified by forward-looking words such as “potential”, “target”, “anticipate”, “believe”, “could”,
“estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. ANGLE assumes no obligation to update the
information included in this presentation, whether as a result of new information, future events or otherwise.

3. © ANGLE plc 2013 Page 3
Highly successful year
Completed the key development phase for the Parsortix
system for capturing circulating tumour cells (CTCs)
Developed a new capability to harvest intact CTCs from
patient blood for DNA analysis
Parsortix system well received by research partners, University
of Surrey Oncology Group and Cancer Research UK’s Paterson
Institute for Cancer Research
Now being evaluated by key opinion leaders in the fields of
cancer diagnosis and treatment
ANGLE is now focused on securing regulatory authorisation
to allow it to address the multi billion pound clinical market
for the treatment of cancer patients

4. © ANGLE plc 2013
Page 4
Financial Results for the year ended 30 April 2013
2013 2012
Statement of Comprehensive Income £’000 £’000
Turnover 969 1,407
Investments portfolio gain 514 (1,346)
1,483 61
Management services (976) (1,229)
Operating costs (1,580) (1,666)
Other income 42 125
Loss before tax (1,031) (2,709)
Statement of Financial Position
Investments 3,961 3,104
Trade and other receivables 453 533
Inventories 63 0
Cash 1,828 1,121
Property, plant and equipment 138 17
Intangible assets 1,080 411
Total assets 7,523 5,186
Comments
Increased investment
principally in Parsortix of
£2.5m up from £1.7m
• Operating costs £1.6m
• Capitalised expenditure £0.9m
Geomerics non-core
investment £4.0m
• Held for sale
• Investment during year £0.3m
• Fair value gain £0.5m
Cash balance strengthened
to £1.8m
Net assets increased 45%
to £7.5m
Equity issues £3.3m

5. © ANGLE plc 2013 Page 5
Medtech capability strengthened
Brian Howlett appointed to the Board in January 2013
−more than 20 years’ experience of building and managing medical device and
diagnostic businesses
−CEO of AIM-quoted Lombard Medical Technologies PLC from 2005 to 2010
−1999 to 2005, UK Country Leader at Boston Scientific Corporation
−Since 2010, Non-Executive Chairman of two privately held medtech companies,
Michelson Diagnostics Limited and Vascular Flow Technologies Limited
Two world-leading Scientific Advisers appointed
−Professor Adrian Newland CBE (no relation to ANGLE’s Chief Executive)
Professor of Haematology at Barts Health NHS Trust and Queen Mary University
of London. Director of Pathology for Barts and Clinical Director of the North East
London Cancer Network
−Professor Ashok Venkitaraman Ursula Zoellner Professor of Cancer Research
at the University of Cambridge. Director of the Medical Research Council’s
Cancer Cell Unit and Joint Director of the Medical Research Council Hutchison
Cancer Research Centre

6. © ANGLE plc 2013 Page 6
Patented micro-fluidic based particle separation technology
Origins in micro-electronics industry – plastics fabrication to
sub-micron tolerances
Separation structures with ‘step’ configurations
Suspended particles flow along a series of channels whose
height progressively decreases at each ‘stair-step’
Particles separated on the basis of their size and skeletal
structure
Parsortix Cell Separation Technology

7. © ANGLE plc 2013
Parsortix Cell Capture
Page 7
Inlet
Outlet
Patented
Separation Step
Plan View
Cross Section
Captured CTCs
White blood cells
Red blood cells
pass through
Blood Flow

8. © ANGLE plc 2013 Page 8
Parsortix GEN3 Cassette successfully developed

9. © ANGLE plc 2013 Page 9
Parsortix PR1 Machine successfully developed

10. © ANGLE plc 2013 Page 10
CE Marked for electrical compliance

11. © ANGLE plc 2013 Page 11
Batch of PR1 Machines on Cogent Technology line

12. © ANGLE plc 2013 Page 12
Parsortix PR1 System set for automated harvesting

13. © ANGLE plc 2013 Page 13
GEN3 cassette: captured PC-3 prostate cancer cells
Lines are the Parsortix cell
separation steps
Two outer Steps (RHS) are
20µm apart. The inner
Steps are 10µm apart
Large PC3 cells are shown
captured on the outer Steps
The PC3 cells are 15 to
25µm in diameter
The image shows a clean
capture without the
presence of WBC or RBC
In the cassette more widely,
there will only be a very low
level of WBC and RBC
PC3 cells captured in GEN3 cassette prior to
fluorescent staining
Blood flow

14. © ANGLE plc 2013 Page 14
System specification
Captures CTCs in cancer patient blood including epithelial,
mesenchymal and clumps of cells
−Runs whole blood automatically without the need for user intervention
−2ml to 4ml blood is typically sufficient. System has capability to run volumes
from 50µl to 50ml
Works with variety of cancers including prostate, breast,
colorectal, lung and renal
−High capture sensitivity. Has successfully captured 9 out of 10 cultured cancer
cells spiked in 8ml of whole blood
−Captures intact, undamaged, viable cells
Does not require the use of antibodies
Simple, Effective, Affordable

15. © ANGLE plc 2013 Page 15
Applications under development
Presence
−Microscope slide capture device enables the morphological examination of
captured cells with clear visibility of cell structure
−Step separation of 20µm allows easy visual sizing of cells
−Automated cell identification possible in situ within the cassette with a choice of
up to 7 reagents e.g. CK18+, DAPI+ and CD45-
Counting
−Microscope slide format enables the user to view and count captured cells
−Indication of disease status and progression
Harvesting
−Automated recovery of intact, undamaged, viable cells allows DNA analysis
−High level of cell purity with only 10 to 100 other cells for each captured CTC
Simple, Effective, Affordable

16. © ANGLE plc 2013 Page 16
Colorectal cancer patient data (Source: University of Surrey)
3rd Party confirmation working well with patient blood
n=20 patient samples
High positive ID of CTCs in 75% of patients – more than double
CellSearch system (Sources: 1. Allard WJ, Matera J, Miller MC et al. Clin Cancer Res 2004; 10:
6897-6904 found 30% of colorectal cancer patients positive for CTCs and 2. Sastre J, Maestro ML, Puente J
et al. Annals of Oncology 19: 935-938, 2008 found 36.2% colorectal cancer patients positive for CTCs.)
Only 2ml blood run. Increased blood volume will lead to
increased CTC capture
High capture rate of up to 45 CTCs in 2ml patient blood
Merged fluorescent images
of colorectal CTCs on
Parsortix step
White blood cell next to
a colorectal CTC
• Red stain for nucleus (PI)
identifies WBC and CTC
• Green stain for cancer (CK20)
• Merged red and green image
identifies CTC

17. © ANGLE plc 2013 Page 17
Cancer Research UK’s Paterson Institute for Cancer Research
Positive evaluation
Key advantages of Parsortix system identified:
−Cell marker (epitope) independent
−“Plug and play”
−Operationally versatile
−Biomarker compatible
Parsortix included in Paterson Institute’s ongoing efforts to
deliver personalised medicine
Use of system with mouse model
−Widely used research approach with biopsied cancer cells from the patient
cultured in vivo in a mouse model
−Existing FDA system needs 7.5ml blood and cannot be used
Automated imaging of DEP
Array showing captured
SCLC CTC
CTC = circulating tumour cell
SCLC = small cell lung cancer

18. © ANGLE plc 2013 Page 18
Market entry
Major areas of current work
Regulatory compliance and documentation (complete)
ISO13485 quality control system
Volume manufacture, supply chain and stock control
Customer support and service processes including technical
support systems
Sales and marketing processes
Sales collateral
Financial control and administration: credit checks, invoicing,
collection, CRM database
Distribution and shipping

19. © ANGLE plc 2013 Page 19
Moving into regulatory authorisation and market launch phase
Objectives for current financial year
Placing the Parsortix system with Key Opinion Leaders
3rd party independent validation of the Parsortix system
Selecting a manufacturing partner and establishing quality
control systems
Plan for regulatory authorisation for the product to be used
in the clinical market
CE Mark authorisation for clinical sales in the European Union
Application to the FDA for authorisation for clinical sales in the
United States
Market entry plan for Parsortix

20. © ANGLE plc 2013 Page 20
Andrew Newland
ANGLE plc
3 Frederick Sanger Road
The Surrey Research Park
Guildford GU2 7YD
United Kingdom
Tel: +44 1483 685830
Fax: +44 1483 685836
Email: andrew.newland@ANGLEplc.com
Website: www.ANGLEplc.com
Contact details